These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 318211)

  • 61. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992.
    Tanaka-Bandoh K; Kato N; Watanabe K; Ueno K
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S352-5. PubMed ID: 7548596
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antimicrobial activity of latamoxef (moxalactam) against both Bacteroides fragilis and Escherichia coli in an intraperitoneal abscess model.
    Harris RW; Moore WL; Arensman JB; Rissing JP
    J Antimicrob Chemother; 1984 Nov; 14(5):499-508. PubMed ID: 6392279
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility.
    Piddock LJ; Wise R
    J Antimicrob Chemother; 1987 Feb; 19(2):161-70. PubMed ID: 3571041
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Purification and characterization of an imipenem hydrolysing metallo-beta-lactamase from Bacteroides fragilis.
    Hedberg M; Edlund C; Lindqvist L; Rylander M; Nord CE
    J Antimicrob Chemother; 1992 Feb; 29(2):105-13. PubMed ID: 1506324
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cefoxitin and cephamycins: microbiological studies.
    Stapley EO; Birnbaum J; Miller AK; Wallick H; Hendlin D; Woodruff HB
    Rev Infect Dis; 1979; 1(1):73-89. PubMed ID: 400941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.
    Hecht DW; Osmolski JR; O'Keefe JP
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S357-60. PubMed ID: 8324147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aspects on antibacterial treatment of anaerobic infections.
    Nordbring F; Nord CE
    Scand J Infect Dis Suppl; 1982; 35():59-62. PubMed ID: 6762654
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recovery of Bacteroides fragilis group from clinical specimens following antimicrobial therapy.
    Brook I; Frazier EH
    Can J Microbiol; 1992 Mar; 38(3):226-9. PubMed ID: 1393825
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chemoprophylaxis with cefoxitin and cephalothin in orthopedic surgery: a comparison.
    Rosenfeld MB; Campos J; Ratzan KR; Uredo I
    Antimicrob Agents Chemother; 1981 May; 19(5):826-30. PubMed ID: 7027924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cefoxitin: its role in treatment and prophylaxis of obstetric and gynecologic infections.
    Counts GW
    Rev Infect Dis; 1988; 10(1):76-91. PubMed ID: 3281224
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Results of a clinical trial of cefoxitin, a new cephamycin antibiotic.
    McCloskey RV
    Antimicrob Agents Chemother; 1977 Nov; 12(5):636-41. PubMed ID: 335968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cefoxitin therapy for bacterial endocarditis.
    Webb D; Thadepalli H; Bach V
    Rev Infect Dis; 1979; 1(1):170-4. PubMed ID: 318219
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The fetid foot: lower-extremity infections in patients with diabetes mellitus.
    Fierer J; Daniel D; Davis C
    Rev Infect Dis; 1979; 1(1):210-7. PubMed ID: 318225
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins.
    Schrogie JJ; Rogers JD; Yeh KC; Davies RO; Holmes GI; Skeggs H; Martin CM
    Rev Infect Dis; 1979; 1(1):90-8. PubMed ID: 318227
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Growth of Bacteroides fragilis in rabbit tracheal organ culture: anaerobiosis and tissue respiration.
    Murakami T; Matsuyama T; Shiraishi S; Hagihara B
    Infect Immun; 1981 Dec; 34(3):1062-4. PubMed ID: 7333664
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Penetration of clindamycin, cefoxitin, and metronidazole into pelvic peritoneal fluid of women undergoing diagnostic laparoscopy.
    Berger SA; Kupferminc M; Lessing JB; Gorea A; Gull I; Peyser MR
    Antimicrob Agents Chemother; 1990 Feb; 34(2):376-7. PubMed ID: 2139315
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clearance of Bacteroides fragilis lipopolysaccharide in vivo.
    Sveen K
    Acta Pathol Microbiol Immunol Scand C; 1985 Feb; 93(1):7-11. PubMed ID: 3984751
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety of cefoxitin: an approach to the analysis of laboratory data.
    Brown KR; Getson AJ; Gould AL; Martin CM; Ricci FM
    Rev Infect Dis; 1979; 1(1):228-32. PubMed ID: 400935
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of septicemic patients with cefoxitin: pharmacokinetics in renal insufficiency.
    Pazin GJ; Schwartz SN; Ho M; Lyon JA; Pasculle AW
    Rev Infect Dis; 1979; 1(1):189-94. PubMed ID: 318220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.